Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03254927
Title A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Celldex Therapeutics
Indications

oropharynx cancer

head and neck squamous cell carcinoma

Therapies

CDX-3379 + Cetuximab

Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
The University of Arizona Cancer Center Tucson Arizona 85724 United States Details
Yale Cancer Center New Haven Connecticut 06511 United States Details
Emory University Winship Cancer Institute Atlanta Georgia 30322 United States Details
Rush University Medical center Chicago Illinois 60612 United States Details
Washington University School of Medicine Saint Louis Missouri 63110 United States Details
University of Cincinnati Cincinnati Ohio 45267 United States Details
University of Pennsylvania Hospital, Abramson Cancer Center Philadelphia Pennsylvania 19104 United States Details
UPMC Hillman Cancer Center Pittsburgh Pennsylvania 15232 United States Details
Medical University of South Carolina Charleston South Carolina 29425 United States Details
Vanderbilt University Medical Center Nashville Tennessee 37232 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field